Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease-Reference-Cited by-同舟云学术

Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease

Published:2017-03 Issue:3 Volume:30 Page:243-255
ISSN:0934-0874
Container-title:Transplant International
language:en
Short-container-title:Transpl Int

Author:

Herzer Kerstin¹,Welzel Tania M.²,Spengler Ulrich³,Hinrichsen Holger⁴,Klinker Hartwig⁵,Berg Thomas⁶,Ferenci Peter⁷,Peck-Radosavljevic Markus⁷⁸,Inderson Akin⁹,Zhao Yue¹⁰,Jimenez-Exposito Maria Jesus¹⁰,Zeuzem Stefan²

Affiliation:

1. Universitätsklinikum Essen; Essen Germany

2. Universitätsklinikum der Johann Wolfgang Goethe Universität; Frankfurt Germany

3. Universitätsklinikum Bonn; Bonn Germany

4. Gastroenterologisch-Hepatologisches Zentrum Kiel; Kiel Germany

5. Universitätsklinikum Würzburg; Würzburg Germany

6. Universitätsklinikum Leipzig; Leipzig Germany

7. Medical University of Vienna; Vienna Austria

8. Klinikum Klagenfurt am Wörthersee; Klagenfurt Austria

9. Leiden University Medical Center; Leiden The Netherlands

10. Bristol-Myers Squibb; Princeton NJ USA

Funder

Bristol-Myers Squibb

Richard Boehme of Articulate Science

Publisher

Frontiers Media SA

Subject

Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tri.12910/fullpdf

Reference32 articles.

1. Liver;Kim;Am J Transplant,2016

2. The burden of liver disease in Europe: a review of available epidemiological data;Blachier;J Hepatol,2013

3. Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting;Beinhardt;Transpl Int,2015

4. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria;Narang;Liver Transpl,2010

5. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C;Bizollon;Am J Transplant,2005

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Phosphatidylcholine Species 32:0 as a Biomarker for Liver Cirrhosis Pre- and Post-Hepatitis C Virus Clearance;International Journal of Molecular Sciences;2024-07-26

2. Direct antiviral therapy for hepatitis C cirrhotic patients in liver transplantation settings: a systematic review;Hepatology International;2022-09-09

3. Sofosbuvir-Velpatasvir Full Dose in Chronic Hepatitis C in End-Stage Renal Disease: An Observational Study from a Himalayan Region;Journal of Gastrointestinal Infections;2022-07

4. Polypharmacology in Clinical Applications: Gastrointestinal Polypharmacology;Polypharmacology;2022

5. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients;Gut and Liver;2020-05-15